Ligand Pharmaceuticals, Inc. (LGND) Tops Q2 EPS by 10c; Boosts FY14 Outlook
Get Alerts LGND Hot Sheet
EPS Growth %: -60.5%
Financial Fact:
Gain on sale of a product line: 0
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q2 EPS of $0.24, $0.10 better than the analyst estimate of $0.14. Revenue for the quarter came in at $10.6 million versus the consensus estimate of $9.73 million.
Ligand Pharmaceuticals, Inc. sees Q3 2014 EPS of $0.26-$0.29, versus the consensus of $0.4. Ligand Pharmaceuticals, Inc. sees Q3 2014 revenue of $13-14 million, versus the consensus of $16.6 million.
Ligand Pharmaceuticals, Inc. sees FY2014 EPS of $1.50-$1.55, versus prior guidance of $1.4-$1.45 and the consensus of $1.44. Ligand Pharmaceuticals, Inc. sees FY2014 revenue of $64-66 million, versus prior guidance of $64-66 million and the consensus of $62.9 million.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Agnico Eagle Mines (AEM) Tops Q1 EPS by 17c
- The Hartford (HIG) Misses Q1 EPS by 13c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!